United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019

Aggarwal, Pushkar; Knabel, Peter; Fleischer, Alan B.

doi:10.1016/j.jaad.2021.03.109

Cited by 106 publications

(79 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was estimated that the national health service spent 180 million pounds in 2020 [ 3 ]. The average annual cost of treating melanoma in the United States was estimated at $3.3 billion from 2007 to 2011, and the average annual cost of treating NMSC was estimated at $4.8 billion, for a total of $8.1 billion [ 9 ]. Current research shows that prevention helps reduce the disease burden, so prevention efforts are positive from every perspective [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years

Fang

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background The disease burden of non-melanoma skin cancer (NMSC) has become a significant public health threat. We aimed to conduct a comprehensive analysis to mitigate the health hazards of NMSC. Methods This study had three objectives. First, we reported the NMSC-related disease burden globally and for different subgroups (sex, socio-demographic index (SDI), etiology, and countries) in 2019. Second, we examined the temporal trend of the disease burden from 1990 to 2019. Finally, we used the Bayesian age-period-cohort (BAPC) model integrated nested Laplacian approximation to predict the disease burden in the coming 25 years. The Norpred age-period-cohort (APC) model and the Autoregressive Integrated Moving Average (ARIMA) model were used for sensitivity analysis. Results The disease burden was significantly higher in males than in females in 2019. The results showed significant differences in disease burden in different SDI regions. The better the socio-economic development, the heavier the disease burden of NMSC. The number of new cases and the ASIR of basal cell carcinoma (BCC) were higher than that of squamous cell carcinoma (SCC) in 2019 globally. However, the number of DALYs and the age-standardized DALYs rate were the opposite. There were statistically significant differences among different countries. The age-standardized incidence rate (ASIR) of NMSC increased from 54.08/100,000 (95% uncertainty interval (UI): 46.97, 62.08) in 1990 to 79.10/100,000 (95% UI: 72.29, 86.63) in 2019, with an estimated annual percentage change (EAPC) of 1.78. Other indicators (the number of new cases, the number of deaths, the number of disability-adjusted life years (DALYs), the age-standardized mortality rate (ASMR), and the age-standardized DALYs rate) showed the same trend. Our predictions suggested that the number of new cases, deaths, and DALYs attributable to NMSC would increase by at least 1.5 times from 2020 to 2044. Conclusions The disease burden attributable to NMSC will continue to increase or remain stable at high levels. Therefore, relevant policies should be developed to manage NMSC, and measures should be taken to target risk factors and high-risk groups.

show abstract

Section: Introductionmentioning

confidence: 99%

Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years

Fang

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…The studies call for more prevention efforts to diagnose melanoma at earlier stages, as life-years spent with disability is lower than life-years lost. Earlier diagnoses could lead to reduced melanoma burden, with life-years lost turning into life-years with disability (37)(38)(39). The studies were published before the onset of novel immunotherapeutic agents, when researches were ongoing in both drug therapies and predictive markers that may also affect melanoma DALY (39).…”

Section: Discussionmentioning

confidence: 99%

Improving Quality Indicator of Melanoma Management – Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study

et al. 2021

View full text Add to dashboard Cite

IntroductionThe incidence of melanoma has been increasing in the last decades. A retrospective Hungarian epidemiological study provided real-world data on incidence and mortality rates. There have been changing trends in incidence in Hungary in the last decade and mortality decreased, shifting mortality-to-incidence rate ratios (MIR). MIR is an indicator of cancer management quality.ObjectivesOur aim is to show the changes of melanoma MIR in Hungary between 2011 and 2018 and to compare the real-world evidence-based results of our Hungarian nationwide retrospective study with other European countries.MethodsMIR is calculated from the age-specific standardized incidence and mortality rates from our study. Annual MIR values are presented for the total population and for both sexes between 2011 and 2018, along with 95% confidence intervals. Comparison with European countries are shown for 2012 and 2018 based on the GLOBOCAN database and Eurostat health care expenditure per capita data.ResultsMIR decreased by 0.035 during the study years. The decrease was same in both sexes (0.031). Male had higher MIRs in all study years. In both 2012 and 2018, Hungarian MIR in both sexes was lower than the European Union average (males: 0.192 vs. 0.212 and 0.148 vs. 0.174 respectively, women: 0.107 vs. 0.129 and 0.083 vs. 0.107 respectively).DiscussionHungarian mortality-to-incidence ratio is the lowest in Central and Eastern Europe and is close to the level of Western and Northern European countries. The results are driven by the high number of new diagnosed melanoma cases.

show abstract

“…Chronic itch data were extracted from the University of Washington Institute for Health Metrics and Evaluation GBD database [10] . GBD is a public database providing global epidemiological data on 354 infections and diseases from 1990 to 2017 [11][12][13] . Data can be sorted by location, year, context, age, metric, measure, sex, and cause.…”

Section: Methodsmentioning

confidence: 99%

Global epidemiology of itch from 1990 to 2017: gender, age, sanitation, and air pollution as risk factors

Kulkarni

Liu

Aggarwal

et al. 2022

Itch

Self Cite

View full text Add to dashboard Cite

Background: Itch is a symptom with significant physical, psychological, and financial burden worldwide. Symptom-specific and demographic risk factors have been published although community-level risk factors have not been thoroughly studied. Objectives: To describe the epidemiological risk factors of itch and to present a hypothesis that can account for these trends. Materials and methods: Itch incidence, prevalence, and years lost to disability (YLD) by age, sex, world region, socio-demographic index, percent of population using basic sanitation services, mortality due to air pollution, and gross domestic product (GDP) per capita were obtained from the University of Washington Institute for Health Metrics and Evaluation Global Burden of Disease (GBD), World Health Organization Global Health Observatory (WHO GHO), and Worldometer databases. Linear regression models were utilized to analyze the relationship of sanitation, air pollution, and GDP with itch incidence, prevalence and YLD. Results: Female sex and age were positively associated with higher incidence of itch. The percent of population using basic sanitation services was also positively correlated with itch incidence, prevalence, and YLD (P<0.001). Mortality rate due to air pollution was negatively associated with itch incidence, prevalence, and YLD (P<0.001). However, GDP per capita was not associated with the incidence (P=0.5), prevalence (P=0.8), and YLD (P=0.7) of itch. Conclusions: The “hygiene hypothesis” might explain global trends of itch as more industrialized countries have higher itch incidence rates. Thus, approaches which target molecular pathways involved in the “hygiene hypothesis” may lead to a decreased global itch burden.

show abstract

United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019

Cited by 106 publications

References 24 publications

Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years

Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years

Improving Quality Indicator of Melanoma Management – Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study

Global epidemiology of itch from 1990 to 2017: gender, age, sanitation, and air pollution as risk factors

Contact Info

Product

Resources

About